NRAS and colorectal carcinoma: Mutations in the entire coding region of the NRAS oncogene as well as in the exon 20 of the PIK3CA gene, which are rarer in CRC patients, have also been demonstrated to be predictors of reduced response to anti-EGFR therapies [36–38].